Kigtropin es el nombre comercial de humanos creados sintéticamente,Kigtropin es la mejor somatropina HGH en el mercado, los resultados más efectivos y mejores que una persona puede obtener, kigtropin está diseñado. Enviamos el pedido desde los EE. UU., china, y UE. Somos distribuidor de?kigtropin HGH mayorista de? kigtropina HGH, Obtenga más kigtropin HGH China (Continente) fabricantes, exportadores, proveedores, fábricas, Empresas de China .
Kigtropin es una hormona de crecimiento humano (hGH) Somatropina producida con tecnología de ADN recombinante idéntica a la HGH producida naturalmente por el cuerpo.
Retraso en el crecimiento de los niños debido a la deficiencia endógena de la hormona del crecimiento (GHD).
En adultos con deficiencia de hormona de crecimiento,KIGTROPIN reduce la masa grasa,aumenta la masa muscular y mejora la energía,vitalidad y bienestar subjetivo. En pacientes que sufren quemaduras graves,Pérdida de masa muscular asociada al SIDA,o sometido a operaciones importantes,KIGTROPIN promueve la cicatrización de heridas,atenúa la respuesta catabólica de proteínas y mejora la condición de nitrógeno de todo el cuerpo después de la operación.
Kigtropin comes as a freeze dried white powder – 10 x 10 IU (3.3 miligramos) vials per box. Like several others it started as a made up brand name which became popular due to good reviews in the bodybuilding community. It is manufactured by an unknown Chinese lab – which seems to be a common practice some Chinese companies use to avoid the HGH legality issues
In patients who continue growth hormone therapy after childhood GHD, the recommended dose to restart is 0.2 - 0.5 mg per day. The dose should be gradually increased or decreased according to individual patient requirements as determined by the IGF-I concentration.
In adults with adult-onset GHD, therapy should start with a low dose, 0.15 - 0.3 mg per day. The dose should be gradually increased according to individual patient requirements as determined by the IGF-I concentration.
In both cases treatment goal should be insulin-like growth factor (IGF-I) concentrations within 2 SDS from the age corrected mean. Patients with normal IGF-I concentrations at the start of the treatment should be administered growth hormone up to an IGF-I level into the upper range of normal, not exceeding the 2 SDS. Clinical response and side effects may also be used as guidance for dose titration. It is recognized that there are patients with GHD who do not normalize IGF-I levels despite a good clinical response, and thus do not require dose escalation. The maintenance dose rarely exceeds 1.0 mg per day. Women may require higher doses than men, with men showing an increasing IGF-I sensitivity over time. This means that there is a risk that women, especially those on oral oestrogen replacement are under-treated while men are over-treated. The accuracy of the growth hormone dose should therefore be controlled every 6 meses. As normal physiological growth hormone production decreases with age, dose requirements may be reduced.
Kigtropin for Elderly:
In patients above 60 años, therapy should start with a dose of 0.1 - 0.2 mg per day and should be slowly increased according to individual patient requirements. The minimum effective dose should be used. The maintenance dose in these patients seldom exceeds 0.5 mg per day.
How to Inject:
The subcutaneous administration of growth hormone may lead to loss or increase of adipose tissue at the injection site. Therefore, injection sites should be alternated.
The injection should be given subcutaneously and the site varied to prevent lipoatrophy.
